Advancing CAR-T Therapy With CD5 Modulation

Deleting the CD5 gene from CAR T-cells improved their expansion, durability, and tumor-killing capabilities, according to a preclinical study led by Marco Ruella, MD, an assistant professor of Hematology-Oncology. Researchers plan to evaluate this CD5 “knockout” approach in a clinical trial of patients with T-cell lymphoma.